775,000,000 million shares O/S soon???? Wow!!!! Almost 725% more than current 105,000,000. Wow!!!! What a bunch of "pooo"...lol
August 2018
Note 3 - Stockholders’ Deficit
We have 8,000,000,000 authorized shares of Common Stock, $0.0001 par value, and 250,000,000 authorized shares of preferred stock, of which 150,000,000 are designated as Series A Preferred Stock, $0.0001 par value. As of June 30, 2018, 104,477,936 shares of Common Stock were issued and outstanding, and 63,038,284 shares of Series A Preferred Stock, convertible into 105,297,802 shares of Common Stock, were issued and outstanding.
In addition, as of June 30, 2018, we have outstanding options to acquire up to 6,800,000 shares of Common Stock, warrants to acquire up to 49,477,380 shares of Series A Preferred Stock (which upon exercise would be convertible into 82,645,958 shares of Common Stock) and warrants to acquire up to 251,513,750 shares of Common Stock. We may issue an additional 224,123,951 shares of Common Stock if holders of secured notes voluntarily convert. If all derivative and convertible securities were fully exercised and converted into Common Stock, there would be a total of 774,859,397 shares of Common Stock outstanding. In addition, we may be obligated to issue an additional 14,000,000 shares of Series A Preferred Stock in exchange for future clinical research services in the amount of $1,050,000.
